Tag: CiiTA
At present most manufacturers are not actively or effectively managing their exposure to 340B duplicate discounts. Current projections of the scope of the issue are severely limited by a lack of data, and many manufacturers are completely unaware of the significance of the problem. Additionally, the data required to identify duplicate claims is difficult to…
Read MorePORTLAND, Ore. – April 25, 2016 — CiiTA founder and managing partner Jason Hardaway is invited to speak at the upcoming third-annual National Leadership Summit on 340B in Washington, D.C. on May 17, 2016. This summit is the annual opportunity for stakeholders to engage in meaningful and transparent dialogue to ensure the 340B program’s future…
Read MoreIt should come as no surprise that CiiTA fully supports the 340B Program and recognizes the important financial role it plays in the healthcare safety net. What might be less obvious is that the vast majority of pharmaceutical manufacturers support 340B as well. (Full disclosure: CiiTA’s client base is almost exclusively drug companies.) The 340B…
Read MoreOver the past year, we here at CiiTA have become increasingly concerned about the potential 340B/Medicaid duplicate discount risk to manufacturers. We recently looked into this for a couple of our clients and found what amounts to a perfect storm of insidious financial exposure: 1) a surge in eligible claims thanks to the ACA-directed Medicaid…
Read MoreOn May 26, 2015 the Centers for Medicare & Medicaid Services (CMS) proposed to make Medicaid managed care organizations (MCOs) responsible for establishing procedures to prevent 340B duplicate discounts in the managed Medicaid setting. In the proposed rule, CMS has clarified that the onus will fall solely on the MCO to create models to prevent…
Read MoreDevelop Your 340B Strategy
CiiTA has, through extensive experience, developed a set of best practices to help guide you through the creation of your 340B strategy. Download our process document to facilitate the development of your strategy.